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ORIGINAL ARTICLE
Efficiency of alternative policy options for screening for
developmental dysplasia of the hip in the United
Kingdom
J Brown, C Dezateux, J Karnon, A Parnaby, R Arthur
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Arch Dis Child 2003;88:760–766
Aims: To assess, using a decision model, the efficiency of ultrasound based and clinical screening
strategies for developmental dysplasia of the hip.
Methods: The additional cost per additional favourable outcome was compared for the following
strategies: clinical screening alone using the Ortolani and Barlow tests; addition of static and dynamic
ultrasound examination of the hips of all infants (universal ultrasound) or restricted to infants with
defined risk factors (selective ultrasound); “no screening” (that is, clinical diagnosis only).
Results: Ultrasound based screening strategies are predicted to be more effective but more costly than
clinical screening or no screening. Estimated total costs per 100 000 live births are approximately £4
million for universal ultrasound, £3 million for selective ultrasound, £1 million for clinical screening
alone, and £0.4 million for no screening. The relative efficiency of selective ultrasound and clinical
screening is poorly differentiated, and depends on how infants are selected for ultrasound as well as
the expertise of clinical screening examiners. If training costs less than £20 per child screened, clinical
screening alone would be more efficient than selective ultrasound. Relative to no screening, each of the
16 additional favourable outcomes achieved as a result of selective ultrasound costs approximately
£0.2 million, while each of the five favourable outcomes achieved through universal ultrasound screen-
ing, over and above selective ultrasound, costs approximately £0.3 million.
Conclusions: Policy choice depends on values attached to the different outcomes, willingness to pay
to achieve these and total budget.
The UK national policy to perform a clinical screeningexamination of the hips on all newborn and very younginfants was first introduced in the mid 1960s to identify
infants considered at increased risk of subsequent develop-
mental dysplasia of the hip (DDH; formerly referred to as con-
genital dislocation of the hip).1 This policy has never been
directly evaluated in a randomised controlled trial and there
has been continued controversy and uncertainty about the
benefits and harms of screening. The possible iatrogenic effect
of avascular of the femoral head is the major disbenefit asso-
ciated with the overtreatment of those with false positive
screening results.2 This has culminated in the present interest,
both nationally and internationally, in the use of ultrasound in
addition to clinical examination.3–5 As a consequence, diver-
gent policies now exist, ranging from the universal use of
ultrasound in Germany6 and Austria,7 to the selective use of
ultrasound in the USA,8 and to clinical screening alone in
Canada.9 Moreover, in the UK, although current policy recom-
mends clinical screening alone, current practice no longer
reflects this policy, with the majority of centres using some
form of ultrasound in the assessment process.10 In the UK, the
National Screening Committee’s Child Health Subgroup is
therefore reviewing current policy.
Although further research is needed to clarify the benefits
and harms of screening and to compare alternative screening
strategies, the reality is that policy decisions will be informed
by existing information on the relative effectiveness, associ-
ated disbenefits, and the costs of alternative strategies. In an
accompanying paper,2 we have used a decision tree model to
compare the clinical effects and performance of clinical
screening alone with ultrasound based screening strategies,
and with “no screening” in order to inform policy decisions.
Our findings suggest that ultrasound screening strategies are
more effective, in terms of the number of favourable outcomes
without recourse to surgery, than either clinical screening
alone or no screening, but clinical screening alone is less
clearly differentiated from no screening. We did not consider
the efficiency of these strategies, however, which is essential
information for decision makers given the ever increasing
pressure to fund health care programmes against a back-
ground of finite resources.
The aim of this paper is, therefore, to compare alternative
ultrasound screening strategies and clinical screening with no
screening in terms of their costs and cost effectiveness, using
the decision tree model presented in our companion paper.2 A
subsidiary aim is to identify areas where research might help
reduce uncertainty relevant to policy decisions.
METHODS
Characterisation of strategies to be compared
Strategies to prevent DDHwhich are applicable to the UKwere
characterised by considering the variety of policies and
practices identified from the literature and a national
survey.10 These strategies are summarised in detail in the
accompanying paper.2 Briefly, three screening strategies were
identified (see table 1). One is based on clinical screening
alone using the Ortolani and Barlow tests to identify infants
with hip instability (that is, current policy), while in the other
two, ultrasound examination of the hips is added to this clini-
cal screening examination in order to identify abnormalities
suggesting hip displacement or instability. In a universal
ultrasound strategy, all infants receive an ultrasound exam-
ination, while in a selective ultrasound strategy this examina-
tion is restricted to infants with a positive Ortolani or Barlow
test and/or with recognised risk factors for DDH, including
breech presentation at delivery or a positive family history. As
the existing policy was introduced without clear evidence of
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the benefits of screening, we included a no screening strategy,
whereby infants are diagnosed following clinical presentation.
This reflects the fact that no screening would still incur costs
associated with the diagnosis and surgical treatment of
infants with DDH. Moreover, the treatment would provide
some health benefits. The decision tree depicting the screening
and clinical pathways for the alternative strategies is
described in the accompanying paper,2 where the sources of
pathway probabilities are also presented.
Costs
Table 2 summarises the unit costs, incurred by the health
service, associated with the screening and management path-
ways. All costs were adjusted to 1999/2000 prices,11 and
considered the costs associated with staff, equipment,
overheads, and consumables. Future costs were discounted at
a rate of 6%.12 In order to estimate the unit costs we first
elaborated how the health service might deliver the screening
programme.
Screening costs
Each screening strategy comprises a clinical examination of
the hips (Ortolani and Barlow tests) together with assessment
for the presence of risk factors in the newborn, and a further
examination at 6 weeks. We assumed that a junior doctor
(senior house officer) performed the first test with risk factor
assessment on the maternity ward, but that a general
practitioner performed the test at 6 weeks.10 A junior doctor’s
time was estimated by consultation with clinicians and valued
as the wage rate, plus oncosts, uprated by 40% to take account
of overheads.13 Published sources of the staff costs associated
with the six week examination were uprated by 40% to take
account of overheads.14
In addition, under the universal ultrasound screening strat-
egy, the costs associated with screening included the cost of an
ultrasound examination on the maternity unit. Staffing levels,
time, and equipment associated with the ultrasound examina-
tion were modelled on information provided by 58 of the 77
radiologists surveyed who, at the time, were members of the
British Society of Paediatric Radiology (BSPR) and were
responsible for the ultrasound service in their unit (details
available from the authors). Visits were also made to two
major centres in the UK operating universal ultrasound
screening, supplemented by discussions with other UK
centres (see acknowledgements). Staff time was valued as the
wage rate derived from published sources,15–18 and uprated to
take account of oncosts and overheads. The annual equivalent
cost of ultrasound equipment was estimated assuming a
lifespan of five years and a discount factor of 6%.19
Management costs
Under the strategy of clinical screening alone, we assumed
that a senior doctor would confirm, by repeat clinical
examination on the maternity ward, the presumptive positive
screening result and refer infants for clinical assessment (that
is, without the use of ultrasound) in orthopaedic outpatients
prior to a decision to treat or discharge.10 The cost of the clini-
cal examination was based on that estimated above for the
initial screen, and assuming this was carried out by a special-
ist registrar. The cost of an initial orthopaedic outpatient con-
sultation was taken from NHS Executive estimates.20
Table 1 Definition of screening strategies
Screening strategy Screening test Positive test result
Clinical screening alone Ortolani and Barlow tests Clinically dislocated or subluxatable hip(s)
Universal ultrasound Ortolani and Barlow tests Clinically dislocated or subluxatable hip(s)
AND OR
Static and dynamic ultrasound imaging Sonographically displaced or unstable hip(s)
Selective ultrasound Ortolani and Barlow tests Clinically dislocated or subluxatable hip(s)
AND OR
Systematic identification of recognised
risk factors for DDH*
Presence of one or more risk factors
*DDH, developmental dysplasia of the hip. Recognised risk factors include breech (non-cephalic)
presentation in third trimester or at delivery, and first degree family history of DDH.










Clinical examination – 1.12 1.12 1.12
Risk factor assessment – 1.12 1.12 1.12
Examination at 6 weeks – 0.78 0.78 0.78
Ultrasound examination – – 18.63 –
Management
Repeat clinical examination on maternity ward – 1.31 – –
Initial outpatient visit – 90.00 121.04 121.04
Follow up outpatient visit prior to decision to treat – – 88.04 88.04
Abduction splinting
Pavlik harness 38.38 38.38 38.38 38.38
Follow up outpatient visit until treatment
discontinued
75.63 75.63 75.63 75.63
Surgical treatment
GP visit if symptomatic presentation 18.00 18.00 18.00 18.00
Open reduction* 2020.00 2020.00 2020.00 2020.00
Closed reduction* 1747.48 1747.48 1747.48 1747.48
Follow up to age 16 years* 1572.00 1572.00 1572.00 1572.00
*Undiscounted costs.
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Under the ultrasound based screening strategies, we
assumed that infants with a presumptive positive screening
result would receive a further clinical examination and an
ultrasound assessment as an outpatient, with an average of
1.5 further outpatient assessments (as reported by Marks and
colleagues21) prior to a decision to treat or discharge. The ini-
tial and follow up outpatient visits were valued from costs
estimated by the NHS Executive.20 To this we added the cost of
an ultrasound assessment modelled on information obtained
from our survey of radiologists and from visits to centres pro-
viding universal screening or selective ultrasound examina-
tions in the UK.
Abduction splinting costs
We assumed that infants with persistent abnormalities
following a positive screening result would be treated with
abduction splinting using a Pavlik harness10 22 fitted as an out-
patient, and that treatment would be monitored by
ultrasound.23 An average of 5.5 further outpatient visits for
clinical, ultrasound, and radiological assessment prior to
discontinuing treatment were based on data collected for the
economic evaluation for the UK Hip Trial22 (personal commu-
nication, Alastair Gray). The Pavlik Harness was costed at
manufacturers’ prices and the costs of initial and follow up
outpatient visits from estimates provided by the NHS
executive.20 The cost of an ultrasound examination was
assumed to be the same as that under the management of
infants with presumptive positive screening results.
Surgical treatment costs
Infants with a presumptive positive screening result but in
whom abnormalities are not confirmed at follow up may
present clinically at a later stage, when abduction splinting is
no longer possible and surgery is required. Similarly, those
with a presumptive negative screening result may present
later with clinical signs or symptoms. With a policy of no
screening we assumed that infants can only present sympto-
matically and that surgery is the only treatment option.
In the absence of longitudinal data, we based assumptions
about the type of surgical treatment given to affected children
on expert opinion. Thus we assumed that initially 30% of
infants presenting symptomatically would require an open
reduction or osteotomy and 70% a closed reduction. Of those
initially treated with a closed reduction, one fifth would
require an open reduction or osteotomy by 3 years of age.24 25
We assumed that children in whom initial abduction splinting
had been unsuccessful would require closed procedures only.
We also assumed that all children presenting symptomatically
were referred by their general practitioner for a specialist
opinion.
The cost of an open reduction was based on costs provide by
the NHS Executive.20 The cost of a closed reduction was not
readily available and so was based on the percentage
difference in cost between a closed and open reduction
presented elsewhere.26 It was assumed that after surgery,
patients would receive, on average, four follow up orthopaedic
outpatients visits annually between their first and fifth birth-
day, and thereafter, annual follow up until the 16th birthday.
The cost of the orthopaedic outpatient visits were based on
NHS executive estimates and included x ray costs.20 For those
children presenting symptomatically, the cost of a GP visit was
taken from published sources.13
Effectiveness
A favourable outcome was defined as normal hip development
assessed by absence of subluxation at skeletal maturity (Sev-
erin hip scores of 1–3 in both hips).27 Probabilities of this out-
come following abduction splinting or surgery were deter-
mined from the literature and used to populate the model in
order to estimate the total number of favourable outcomes, per
100 000 live births, associated with each screening strategy
(details are given in the accompanying paper2).
Investigating uncertainties in probabilities, outcomes,
and costs
Using extreme but plausible ranges, taken where possible
from the literature review, the sensitivity analysis explored the
extent to which uncertainties in the costs, screening test per-
formance, service configurations for management, rates of
abduction splinting or surgery, and effectiveness of treatment
influenced our assessment of the relative efficiency of the
strategies.
Modifications to current policy
As the expertise of the primary screener has been identified as
an important factor in the effectiveness of the current
policy,4 28–31 we investigated the potential impact of using more
experienced examiners by modelling a false negative rate of
0.24 per 1000 live births, equivalent to the average detection
rate of 80% reported from centres using more experienced or
specifically trained staff to screen (physiotherapists or ortho-
paedic specialists).29 30 32–36
The impact of using ultrasound to inform the management
of infants with clinical hip instability (positive Ortolani or
Barlow tests), as assessed in the UK Hip Trial22 was
investigated. Costs of ultrasound were added to the follow up
costs of those screened positive in the “clinical screening
alone” strategy. In addition we assumed that all those with a
true positive screening diagnosis were treated initially with
abduction splinting—that is, there were no failures of diagno-
sis among those screening positive.37 Finally we investigated a
combination of these two modifications to current policy.
RESULTS
As reported in the accompanying paper,2 ultrasound screening
strategies are more effective, than either no screening or clini-
cal screening alone, in terms of the number of favourable out-
comes achieved,whereas clinical screening alone is less clearly
differentiated from no screening. Ultrasound based strategies
are, however, more costly (table 3).
We assessed the efficiency of each screening strategy
relative to no screening by comparing the cost of each
Table 3 Costs, favourable outcomes*, and incremental cost-effectiveness ratios of















No screening 380596 89.90 – – –
Clinical screening alone 1014537 94.05 633941 4.15 152757
Selective ultrasound 2841295 106.15 2460699 16.25 151428
Universal ultrasound 4394515 110.83 4013919 20.93 191778
*Favourable outcome refers to radiological appearances at skeletal maturity of Severin grades 1, 2, or 3.
†Compared with no screening.
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additional favourable outcome as indicated by the incremental
cost-effectiveness ratios shown in table 3. These are presented
graphically in fig 1, with each line representing a screening
strategy and the slope of the line the incremental cost-
effectiveness ratio for that strategy relative to no screening.
The incremental cost-effectiveness ratios (and therefore the
slopes) for selective ultrasound and clinical screening are very
similar, suggesting that the efficiency of these strategies is
poorly differentiated.
Nonetheless, clinical screening alone is inefficient under the
base case assumptions, since it produces fewer favourable
outcomes than selective ultrasound and at a higher cost per
additional unit of effect. We thus excluded this strategy and
estimated the additional costs and additional effects associ-
ated with a strategy of universal ultrasound over and above
selective ultrasound (table 4). This suggests that, relative to
selective ultrasound, a strategy of universal ultrasound would
cost about a further £1.5 million per 100 000 live births, or
£0.3 million per additional favourable outcome (table 4).* This
ratio is depicted in fig 1 as the gradient of the dotted line join-
ing the plots for selective ultrasound and universal ultra-
sound. The key findings of the sensitivity analyses are
presented in table 5 (available on the ADC website; www.
archdischild.com/supplemental) and are summarised here.
Uncertainties differentiating the policy choice between
selective use of ultrasound and clinical screening alone
As well as the obvious effect of increasing the cost of
ultrasound, the sensitivity analyses showed two areas of
uncertainty, all within the selective ultrasound strategy, which
are likely to have a major influence on the relative efficiency of
clinical screening alone and selective use of ultrasound. These
are: the criteria used to select “high risk” infants for
ultrasound and the probability of abduction splinting follow-
ing a positive screening result.
We investigated uncertainty in the criteria used to select
“high risk” infants for ultrasound by varying the percentage of
infants with a positive screening result from the base case of
8.1% to 13%, as reported from some UK centres operating this
policy.38 Under this assumption, clinical screening alone
becomes the efficient option. In contrast, assuming a
restricted definition of high risk, such that 4.8%39 are selected
for ultrasound, increases the efficiency of selective ultrasound.
Thus the efficiency of selective use of ultrasound appears to
depend crucially on the way in which “high risk” is defined.
We investigated clinical uncertainty in the indications for
splint treatment in a selective ultrasound strategy by varying
the probability of abduction splinting following a positive
screening result. If we assume a splint rate of 14 per 1000 live
births in this strategy (as reported by Rosendahl and
colleagues40), the costs rise, although effectiveness changes
very little and clinical screening alone becomes an efficient
option. Conversely, a low rate of treatment, 4 per 1000,
modelled from data reported from a specialist UK centre,41
makes clinical screening inefficient.
Uncertainties affecting the policy choice of universal
ultrasound
As well as the obvious effect of increasing the cost of
ultrasound, the sensitivity analyses showed three areas of
uncertainty, two within the selective ultrasound strategy and
one within universal ultrasound, which are likely to have a
major influence on the relative efficiency of these two
strategies. Within the selective ultrasound strategy, these
uncertainties are in the criteria used to select “high risk”
infants for ultrasound (discussed above), and in the false
negative rate for selective ultrasound. If the latter is varied to
the higher levels reported from some UK programmes41 (0.73
per 1000, equivalent to a detection rate of 48%), the effective-
ness and, therefore, efficiency of selective ultrasound de-
creases and selective and universal ultrasound become very
similar in terms of efficiency.
In the universal ultrasound strategy, uncertainties in the
probability of abduction splinting in universal ultrasound are
influential. If we assume the probability of abduction splinting
following a positive screening result to be as high as the aver-
age reported from European centres operating such a policy
(44 per 1000 live births),40 42 43 universal ultrasound becomes
very costly and less efficient (total cost: £6 million per 100 000
live births).
Uncertainties affecting the policy choice of no screening
The most important factor, identified by the sensitivity analy-
ses,whichmade any screening strategy less well differentiated
from no screening was the probability of an unfavourable out-
come following surgical treatment. If the outcome following
surgical treatment is better than assumed in the baseline
(modelled by halving the probability of an unfavourable out-
come after surgery), then all screening strategies become less
well differentiated in terms of effectiveness from no screening
(fig 2). Under this scenario, clinical diagnosis and
management—that is, no screening, produce 105 favourable
treatment outcomes compared with 107, 112, and 115 respec-
tively for clinical screening, selective ultrasound, and universal
ultrasound, respectively. By contrast, if the outcome following
surgery is worse than assumed at baseline (modelled by dou-
bling the probability of an unfavourable outcome), then all
screening strategies become well differentiated from no
screening. Varying the effectiveness of treatment with abduc-
tion splinting does not change the conclusions reached in the
baseline analysis (fig 2).
Figure 1 Incremental cost-effectiveness ratios of alternative
strategies.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
*Current exchange rate: £1 ≡ US$1.5 or &1.5 (approx).
Table 4 Costs, favourable outcomes*, and
incremental cost-effectiveness ratios of the different
screening strategies when compared with the next












Selective ultrasound‡ 2460699 16.25 151428
Universal ultrasound§ 1553220 4.68 331885
*Favourable outcome refers to radiological appearances at skeletal
maturity of Severin grades 1, 2, or 3.
†Recalculated after excluding inefficient screening strategy identified
in table 3.
‡Compared with no screening.
§Ccompared with clinical screening with selective ultrasound.
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Modifications to current policy
Clinical screening alone, when undertaken by more experi-
enced examiners, becomes as effective but more efficient than
selective ultrasound. The total annual cost of screening, diag-
nosis, and management would fall to about £0.8 million per
100 000 live births, reflecting reduced surgical costs. This cost
does not include any costs attributable to the extra training
required. A threshold analysis showed, however, that up to £20
per child screened would be available for training before the
efficiency of clinical screening and selective ultrasound were
similar.
If ultrasound is used to aid the management of infants with
clinical hip instability, clinical screening alone becomes an
efficient policy and its effectiveness improves, but it remains
less effective than the ultrasound strategies.
Finally,we considered both these modifications in combina-
tion (excluding the additional training costs). Under this sce-
nario, clinical screening alone becomes the most effective (112
favourable outcomes) as well as the least costly screening
strategy (£0.9 million per 100 000 live births). Relative to no
screening, each favourable outcome achieved in this scenario
costs approximately £0.02 million.
DISCUSSION
In this paper we distinguished four strategies amenable to
policy, in the UK, and used decision analysis to make explicit
those factors differentiating the strategies in terms of their
effects, costs, and efficiency.44 As discussed in our accompany-
ing paper,2 the modelling presented here is based, of necessity,
largely on observational rather than experimental studies. In
particular there has been only limited experimental evalua-
tion of screening or treatment and there are a paucity of stud-
ies reporting longer term outcomes. However, our analysis
does serve to identify issues that are in need of more rigorous
evaluation, and in the interim, provides an accessible
framework for decision making by integrating the available
data.
Historically the decision to start screening was driven by the
perceived delay in diagnosis and poor outcome for children of
surgery at that time. Our model predicts that almost three
quarters of affected childrenmight expect to have a favourable
outcome with no screening—that is, with clinical diagnosis
and management alone. However, all affected children will
require at least one surgical procedure which is associated
with periods of immobility and, as shown in the accompany-
ing paper,2 an increased risk of avascular necrosis. The policy
choice between screening and no screening is most sensitive to
the extent to which surgery achieves favourable outcomes: the
more successful surgery, the harder it is to justify screening on
the grounds of improved radiological outcome.
The ultrasound based screening strategies appear to be
more effective than no screening in that they produce more
favourable outcomes for those affected, largely without
recourse to surgery.2 However, in efficiency terms, policy
choices between clinical screening alone and selective use of
ultrasound depend crucially on the criteria used to define risk
for selective use of ultrasound, the abduction splinting
treatment rates in this strategy, as well as the costs of
ultrasound. We have highlighted the existing uncertainty in
definition of risk.10 This uncertainty has implications for
important disbenefits, namely those related to avascular
necrosis, following treatment of those with false positive
diagnoses,2 as well as for efficiency. While the findings of the
UK Hip Trial22 suggest that ultrasound imaging of infants with
clinical hip instability allows abduction splinting treatment to
be reduced without apparent adverse effects, there is very little
similar evidence for infants with risk factors but without
clinical hip instability. In the UK there is evidence to suggest
clinical equipoise regarding the effectiveness of abduction
splinting for infants with risk factors but stable hips. However,
the findings of one small randomised trial in this group were
inconclusive,45 suggesting the need for a larger randomised
controlled trial to define treatment benefit in such infants.
A policy of offering ultrasound to all infants appears to be
most effective (producing favourable outcome in 92% of those
affected). The risk of avascular necrosis, however, depends
crucially on thresholds for treatment with abduction
splinting, as shown by sensitivity analyses modelling abduc-
tion splinting rates reported from universal ultrasound
programmes in other European countries.40 42 43 Universal
ultrasound would also be very resource intensive. Were
universal ultrasound screening to be implemented throughout
the UK, assuming approximately 700 000 births per year,46 the
total annual cost of screening, diagnosis, and management
would be of the order of £31 million. Indeed it may even be the
case that the £20 million per annum required to implement a
policy of selective use of ultrasound throughout the UK is
constrained by its budgetary requirements. Clinical screening
alone would cost approximately £7 million and reliance on
clinical diagnosis and management without screening for the
same population would cost approximately £3 million. By
contrast, universal neonatal screening for hearing loss, which
is currently being piloted for implementation, is estimated to
cost at least £12 million per annum (uprated to 1999/2000
prices).47
Relative to no screening, the efficiency of clinical screening
alone depends critically on the skill of the primary examiner,
which in turn reflects the false negative rate. This is consistent
with the results of an earlier study by Tredwell.26 Modifying
the existing policy, by improving the expertise of primary
examiners and by using ultrasound examination to image
those with clinical hip instability, might be an efficient
alternative to abandoning screening. These issues have been
discussed in an accompanying paper.2 Although there is some
evidence from a prospective study48 and from a quality
improvement initiative49 that better training and/or different
personnel can reduce the number of children first diagnosed
with DDH in late infancy, further research in approaches to
Figure 2 The effect of changing the probability of an unfavourable
outcome following treatment.
764 Brown, Dezateux, Karnon, et al
www.archdischild.com
 on 28 August 2008 adc.bmj.comDownloaded from 
training would be helpful as there is limited consensus even
among experts as to what constitutes an acceptable clinical
screening examination.50
Although there have been other studies regarding the effec-
tiveness and cost-effectiveness of hip screening,26 51–61 these
have tended to concentrate on estimating the costs of alterna-
tive strategies and test performance, for example, in terms of
the number of late cases avoided or cases detected by walking
age, rather than outcomes at skeletal maturity. Moreover,
studies have not been comprehensive in their inclusion of
strategies,58 60 61 while some have evaluated options which are
not considered as viable in the UK, such as vibration
arthrometry54 or pelvic x ray.52 53 The advantages of the present
study include the fact that the effectiveness measure captures
the long term outcomes at skeletal maturity and that the
alternatives evaluated are those currently relevant to the UK.
As far as possible the unit costs were estimated to reflect the
marginal or extra costs of each activity (see table 2) associated
with the alternative strategies. Average costs taken from pub-
lished sources were used, however, for the cost of outpatient
visits and surgical treatments. The estimates of surgical costs
were nonetheless similar to those reported in the study
reported by Clegg and colleagues.61 Further comparisons with
that study are not possible as it did not report the longer term
outcomes. Our model did not consider the costs of treatment
beyond skeletal maturity, such as those associated with hip
replacement or treatment of avascular necrosis, as reliable
information beyond the age of skeletal maturity is not
available. We also did not estimate the costs associated with
training or quality assurance as UK models are lacking.
The definition of a favourable outcome used in the model to
address the relevant efficiency of alternative strategies was
based on radiological outcome and is the best objective meas-
ure available at present. It may not, however, fully reflect the
outcomes most valued by parents. For example, the avoidance
of surgery is emphasised by parents groups as being an
important concern. The outcome measure also does not com-
bine, at a population level, the value of the benefits of normal
hip development and the avoidance of corrective surgery or
the avoidance of possible hip replacement in early adult life,
with the disbenefits of avascular necrosis which could be cap-
tured with utility measures.19 Given the time constraint and
methodological challenges associated with utility measure-
ment, however, the latter are presented here in a disaggregated
form and subject to a value judgement.
The choice between the three screening options and no
screening thus depends on the values attached to the different
outcomes, how much service providers are willing to pay to
achieve these, as well as the total budget available. In the
longer term, the model suggests research is needed into meas-
uring the utility values assigned to the screening outcomes,
the effectiveness of abduction splinting in children with risk
factors but stable hips, and into methods for improving the
expertise of examiners responsible for clinical screening.
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